- Price
- $85.11
- Day
- -1.42%
- Mkt Cap
- $11.99B
- 52W Range
- $27.15 – $95.49
- Volume
- 1.57M
- Beta
- 1.28
Find a company by name or ticker and open its page
Snapshot of fundamentals, performance, and 5D scores.
Business fundamentals and company information
Recent price action and historical returns
How the business makes money, by product and geography
Five lenses on the stock. Click any card to dive deeper.
How to read these dimensions
The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.
Recent news headlines and analyst price-target moves
Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million
The transaction was valued at $1 million. The sale reduced the director's direct equity holdings by 9%.
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: 2026 Cantor Global Healthcare Conference – September 9-11, 2026 Type: Fireside Chat Presentation Date/Time: September 10, 2026, 10:55 am EDT Morgan Stanley 24th Annual Global Healthcare Conference – September 14-16, 2026 Type: Fireside Chat Presentation Date/Time: September 15, 2026, 11:30 am EDT H.C. Wainwright 28th Ann.
Benjamin Edwards Inc. Makes New $721,000 Investment in Arrowhead Pharmaceuticals, Inc. $ARWR
Benjamin Edwards Inc. purchased a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 8,841 shares of the biotechnology company's stock, valued at approximately $721,000. Several other hedge funds and other institutional
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasiran in Severe Hypertriglyceridemia Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasiran in Severe Hypertriglyceridemia Transcript
Arrowhead's Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials
Arrowhead Pharmaceuticals NASDAQ: ARWR presented 12-month results from its Phase 3 SHASTA-3 and SHASTA-4 trials evaluating plozasiran in adults with severe hypertriglyceridemia, reporting substantial reductions in triglycerides and acute pancreatitis events versus placebo. The company said the data were presented at the European Society of Cardiology Congress in Munich and have been accepted for publication in a major medical journal.